Billionaire Piramal expects pharma unit demerger by end of 2022: Bloomberg

"The demerger process is going on. We expect, with all regulatory approvals, it should be done somewhere in the October to December quarter of 2022," Chairman Piramal told Bloomberg TV Friday.

Read also: Piramal Pharma adds scale roller compactor at Pennsylvania facility

He added that weaning off dependence on China for drug ingredients was a "big challenge" and would take a few years despite a policy push from the federal government toward paring that reliance to avoid future supply chain disruptions.

Read also: Piramal Pharma Solutions expands, upgrades UK facilities

The financial services flank within Piramal Enterprises -- the other main business within the company -- can see a "secular growth" of 15% as long as the underlying Indian economy continues to be robust, he said.

When asked about succession planning at the group, Piramal said his daughter, Nandini, was already overseeing the health care business while his son, Anand, was in charge of the financial services and the unlisted realty unit.

Read also: Piramal Pharma appoints Anita Marangoly George as Independent Director